Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 187

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 187
---
 an exercise price per share of $11.50, contained in the units sold at a price of $10.00 per unit in the IPO. The Common Stock being registered for resale in connection with this offering will constitute a considerable percentage of our outstanding shares of Common Stock. We are registering for resale on behalf of the Selling Securityholders an aggregate of 20,319,406 shares of Common Stock, not including the shares underlying the Warrants. The shares of Common Stock being registered for resale in this prospectus (excluding the shares underlying the Warrants) constitutes approximately 78.1% of our total outstanding shares. The Selling Securityholders, including Chris Kim, Liminatus’ Founder and our Chief Executive Officer, the beneficial owner of approximately 23.7% of our outstanding shares of Common Stock, will be able to sell all of their shares for so long as the registration statement of which this prospectus forms a part is available for use. Given the substantial amount of redemptions in connection with the Business Combination and the relative lack of liquidity in our stock, sales of our Common Stock under the registration statement of which this prospectus is a part could result in a significant decline in the market price of our securities. In addition, a portion of the Common Stock being registered for resale hereunder were purchased by the Selling Securityholders at prices below the current market price of our Common Stock and, accordingly, may be or are incentivized to sell them under the registration statement of which this prospectus is a part (for example, the Sponsor purchased the founder shares at a price per share of $0.004). The Selling Securityholders may be incentivized to sell their securities even if the prevailing trading price of such securities is at or significantly below the IPO price, because the prices at which they acquired their shares may be lower than prevailing market prices and/or the prices at which public investors purchased our securities in the open market, and therefore such Selling Securityholders may generate positive rates of return on their investment that would not be available to public shareholders that acquired their securities at higher prices. For example, based on the closing price of our Common Stock of $12.11 per share as of June 16, 2025, the shares purchased by the Sponsor would experience a potential profit of up to approximately $12.106 per share with respect to sales of the Common Stock received in consideration of the founder shares. The table below provides, as of the date of this prospectus, information regarding the beneficial ownership of our shares of Common Stock and W